FT. MYERS, Fla.,
Feb. 5, 2013
/PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter and full year 2012 financial results on
Thursday February 14, 2013
The Company has scheduled a web-cast and conference call to discuss their Q4 and full year 2012 results on
February 14, 2013
11:00 AM EST
. Interested investors should dial (800) 374-1317 (domestic) and (404) 665-9940 (international) at least five minutes prior to the call and ask for Conference ID 97486925. An archive of the conference call will be available at
for a period of one year from the date of the conference call. The web-cast may be accessed under the Investor Relations section of our website at
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.
Fort Myers, FL
, NeoGenomics has labs in
, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout
the United States
. For additional information about NeoGenomics, visit
Interested parties can also access investor relations material from Hawk Associates at
and from Zack's Investment Research at
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.